Alkermes is a worldwide pharmaceutical company that develops controlled, sustained-release injectable drugs using with its trademark ProLease and Medisorb technologies. Located in Massachusetts, the company also develops inhaled formulations from its proprietary pulmonary technology. Alkermes has partnered with Johnson & Johnson to develop Riserpdal Consta, an antipsychotic drug used in the treatment of schizophrenia. Risperdal Consta is approved for sale in more than 50 countries that include the United States, United Kingdom and Germany. In addition to a host of partnered products, the ocmpany is also active in the development of several promising proprietary products, such as Vivitrex, a long-acting injectable form of naltrexone for alcohol dependence. Alkermes is headquartered in Cambridge, Mass.

Website: alkermes.com

Phone: (781) 609-6000